Nesfatin-1 inhibits proliferation and enhances apoptosis of human adrenocortical H295R cells

Manjunath Ramanjaneya^{1,2}, Bee K Tan^{1,3}, Marcin Rucinski⁴, Mohamed Kawan¹, Jiamiao Hu¹, Jaspreet Kaur¹, Vanlata H Patel¹, Ludwik K Malendowicz⁴, Hanna Komarowska⁵, Hendrik Lehnert^{1,6} and Harpal S Randeva^{1,7,8}

¹Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK

²Interim Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar

³Department of Obstetrics and Gynaecology, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK

⁴Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland

⁵Department of Endocrinology, Metabolism and Internal Medicine, University of Medical Sciences, 16 Karol Marcinkowski, Poznan, Poland

⁶1st Medical Department, University of Lübeck Medical School, Lübeck, Germany

⁷Department of Diabetes, Endocrinology and Metabolism, University Hospital, Coventry CV2 2DX, UK

⁸Aston Medical Research Institute, School of Life and Health Sciences, Aston University, Birmingham, UK

Correspondence
should be addressed
to H S Randeva

Email
Harpal.Randeva@
warwick.ac.uk

Abstract

NUCB2/nesfatin and its proteolytically cleaved product nesfatin-1 are recently discovered anorexigenic hypothalamic neuroproteins involved in energy homeostasis. It is expressed both centrally and in peripheral tissues, and appears to have potent metabolic actions. NUCB2/nesfatin neurons are activated in response to stress. Central nesfatin-1 administration elevates circulating ACTH and corticosterone levels. Bilateral adrenalectomy increased NUCB2/nesfatin mRNA levels in rat paraventricular nuclei. To date, studies have not assessed the effects of nesfatin-1 stimulation on human adrenocortical cells. Therefore, we investigated the expression and effects of nesfatin-1 in a human adrenocortical cell model (H295R). Our findings demonstrate that NUCB2 and nesfatin-1 are expressed in human adrenal gland and human adrenocortical cells (H295R). Stimulation with nesfatin-1 inhibits the growth of H295R cells and promotes apoptosis, potentially via the involvement of Bax, BCL-XL and BCL-2 genes as well as ERK_{1/2}, p38 and JNK1/2 signalling cascades. This has implications for understanding the role of NUCB2/nesfatin in adrenal zonal development. NUCB2/nesfatin may also be a therapeutic target for adrenal cancer. However, further studies using *in vivo* models are needed to clarify these concepts.

Key Words

- ▶ adrenal cortex
- ▶ apoptosis
- ▶ nesfatin-1
- ▶ NUCB2

Journal of Endocrinology
(2015) 226, 1–11

Introduction

Optimal development of adrenal tissue requires a balance between cell proliferation and apoptosis (programmed cell death); apoptosis removes harmful, damaged or unwanted cells. Within the adrenal gland, constant dynamic changes control the rate of cell growth as a result of

alterations in physiological and pathophysiological conditions (Keegan & Hammer 2002, Kirschner 2002). Regulation of adrenocortical cellular growth is a critical process in adrenal remodelling, especially during embryonic and postnatal development in humans and primates

(Sucheston & Cannon 1968, Ducsay *et al.* 1991). Cell death by apoptosis in the adrenal gland is one of the most common causes of adrenal failure in adrenocortical atrophy (Maisey & Lessof 1969). Many centrally active neuropeptides and molecules, including neuropeptide Y, ghrelin, adipokines such as TNF α , regulate adrenocortical cell growth by altering intracellular signalling cascades leading to dysregulated growth of adrenocortical cells.

Nesfatin-1 is a recently discovered hypothalamic polypeptide derived from its precursor protein nesfatin/nucleobindin2 (NUCB2; Oh-I *et al.* 2006). Nesfatin-1 is abundantly expressed in various regions of the hypothalamus and the regions of the brain involved in the regulation of food intake (Elmqvist *et al.* 2005). NUCB2/nesfatin neurons are activated in response to stress, and central administration of nesfatin-1 elevates circulating adrenocorticotrophin and corticosterone (Stengel & Taché 2011). Bilateral adrenalectomy resulted in increased NUCB2/nesfatin mRNA levels in the paraventricular nuclei of rats, suggesting the importance of NUCB2/nesfatin in the regulation of the hypothalamic–pituitary–adrenal axis (Könczöl *et al.* 2010). NUCB2/nesfatin is also widely expressed in peripheral tissues including the stomach, pancreas as well as in adipose tissue, and regulates various physiological and pathological processes; the main function being suppression of food intake via a leptin independent pathway (Oh-I *et al.* 2006, Shimizu *et al.* 2009). Recent studies have associated NUCB2/nesfatin with various forms of cancer. The expression of NUCB2/nesfatin was found to be higher in breast and prostate cancer patients (Suzuki *et al.* 2012, Zhang *et al.* 2013a). A positive correlation was observed between NUCB2/nesfatin, seminal vesicle invasion, lymph node metastasis, angiolymphatic invasion and a higher Gleason score in prostate cancer. More importantly, a poor overall survival rate was observed in patients with prostate cancer patients who had higher NUCB2/nesfatin levels (Zhang *et al.* 2013a,b, 2014). However conflicting observations were found in lung cancer patients, with circulating nesfatin-1 concentrations being lower in lung cancer patients who have undergone weight loss (Cetinkaya *et al.* 2013). In another study, nesfatin-1 inhibited the proliferation of a human ovarian epithelial carcinoma cell line (Xu *et al.* 2013). We have previously reported nesfatin-1 as a novel adipokine produced from adipocytes and that the circulating and cerebrospinal fluid levels are altered in obese individuals (Ramanjaneya *et al.* 2010, Tan *et al.* 2011). Adipokines have been implicated in the pathophysiology of metabolic disorders (Lewandowski *et al.* 2008, Tan *et al.* 2009,

Adya *et al.* 2012, Randeve *et al.* 2012), and have been shown to have direct effects on the adrenal glands (Kargi & Iacobellis 2014). Given the reports from Ehrhart-Bornstein *et al.* (2004) demonstrating the existence of intra-adrenal fat, and that the adipokines released regulate adrenal secretion in an autocrine and paracrine manner, we aim to investigate the expression of NUCB2/nesfatin in human adrenal gland and human adrenocortical cells (H295R), as well as the effects of nesfatin-1 on H295R cells. H295R cells are pluripotent adrenocortical cells capable of producing all major zone-specific adrenal steroids (Rainey *et al.* 1994).

Materials and methods

Biochemical reagents

Human nesfatin-1 peptide and nesfatin-1 antibody was obtained from Phoenix Pharmaceuticals, Inc. (Belmont, CA, USA). Insulin–transferrin–selenium (ITS) and Ultrosor G were purchased from Pall Life Sciences (Cergy, France). Growth supplement for H295R cells was obtained from Sigma–Aldrich. Accutase required for splitting cells was bought from Cellworks (Buckingham, UK). ECL plus western blotting detection reagents was obtained from GE Healthcare (Little Chalfont, UK). Agarose was obtained from MBI Fermentas, Helena Biosciences (Sunderland, UK). phospho-ERK1/2, phospho-p38, phospho-JNK1/2, ERK1/2, p38 and JNK1/2 antibodies were purchased from Cell Signaling Technology, (Beverly, MA, USA). Polyclonal HRP-conjugated goat anti-rabbit, anti-mouse immunoglobulin/HRP was obtained from Dako (Ely, UK). Precision Plus Protein Standard was obtained from Bio-Rad Laboratories Ltd. A PVDF membrane was obtained from GE Healthcare. All of the primers were obtained from TAGN (Gateshead, UK). Human adrenal glands were obtained under ethical approval, Department of Endocrinology, Metabolism and Internal Medicine, Karol Marcinkowski University of Medical Sciences (Poznan, Poland), bioethics approval number: 556/13.

Cell culture

H295R human adrenocortical cells were cultured in H295R complete media containing DMEM/F12 (1:1) supplemented with 2% Ultrosor G and ITS, in six-well plates (BD Biosciences Discovery Labware (Bedford, MA, USA) for 24 h after reaching confluence. Media was replaced with 2 ml fresh media containing different agents and cultured for <1 h for MAPK experiments, 4 and 24 h for steroidogenic acute regulatory protein (StAR) gene

expression studies. DNA fragmentation and apoptosis studies were done following 24 h stimulation with nesfatin-1 in 96-well plates. At the end of the incubation period, cells were washed with ice-cold PBS and subjected to RNA extraction and analysis as described in the following section.

Y1 mouse adrenal tumour cells (a gift from Prof. Henrik Oster, University of Lübeck, Germany) was grown in DMEM supplemented with 15% horse serum, 2.5% fetal bovine serum and 1% penicillin/streptomycin. The cells were incubated in a humidified atmosphere at 5% CO₂ at 37 °C.

Total RNA extraction and cDNA synthesis

Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen Ltd), according to the manufacturer's guidelines. The purity of the extracted RNA was measured by a NanoDrop spectrophotometer (Labtech International, Ringmer, UK). A set concentration of RNA was reverse transcribed into cDNA, using M-MuLV Reverse Transcriptase (Fermentas, York, UK) and random hexamers (Promega) as primers.

RT-PCR

NUCB2 gene expression was measured by RT-PCR, using 1 µg total RNA and random hexamer primers as RT primers. A control reaction that omitted reverse transcriptase was included to check for the presence of genomic DNA. The concentration of target mRNA were measured by RT followed by real-time PCR performed on a Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies Ltd., Paisley, Renfrewshire, UK), according to the manufacturer's instructions. For analysis, quantitative amounts of the gene of interest were standardized against the housekeeping gene GAPDH. Negative controls for all the reactions included preparations lacking cDNA or RNA-lacking reverse transcriptase in place of the cDNA. The relative mRNA levels were expressed as a ratio using the 'Delta-delta method' for comparing relative expression results between treatments in real-time PCR (Pfaffl 2001). The sequences of the sense and anti-sense primers used were NUCB2: 5'-GCCAGAACGTGTTACGAGTC-3' and 5'-GTCCTCCACCTCATGTTTCAG-3'; StAR: 5'-GGCTACT-CAGCATCGACCTC-3' and 5'-CATCCCACTGTCACCA-GATG-3'; GAPDH: 5'-TGAACGGGAAGCTCACTGG-3' and 5'-TCCACCACCCTGTTGCTGTA-3'; BCL-XL: 5'-ACT: GTG: CGT: GGA: AAG: CGTAG-3' and 5'-GGTTCCTCGG-TGGCAATG-3'; BCL2: 5'-GAGGTCACGGGGGCTAATT-3

and 5'-GAGGCTGGGCACATTACTG-3'; Bax: 5'-ATGGA-GCTGCAGAGGATGAT-3' and 5'-CAGTTGAAGTTGCCG-TCAGA-3'; p53: 5'-GTGGAGTATTTGGATGACAGAAAC-3' and 5'-GTAGTTGTAGTGGATGGTGGTAC-3'. PCR products were stained with ethidium bromide and visualized by electrophoresis through 1.5% agarose gels. Sequencing of the PCR products confirmed the sequence identities. The housekeeping gene was selected following geNorm analyses of five to six housekeeping genes using the geNorm kit (Primer Design, Southampton, UK). The housekeeping gene that was stably expressed in H295R cells was selected as reference gene. The efficiency of primers used for RT-PCR in our manuscript was evaluated by performing a tenfold dilution series experiment. The efficiency of the RT-PCR was calculated from slope generated by ABI 7500 Software version 2.0.6 (Life Technologies). Efficiency of all the primers used in the study was between 90 and 100%.

Western blotting

Protein lysates were prepared by adding equal amounts of Laemmli buffer to each well, and samples were denatured by sonication and boiling. Samples were separated by SDS-PAGE (10% resolving gel) and transferred to PVDF membranes at 100 V for 1 h in a transfer buffer containing 20 mM Tris, 150 mM glycine and 20% methanol. The PVDF membranes were incubated with primary antibody for nesfatin-1, phospo-ERK1/2, phospo-p38 and phospo-JNK1/2 or total-ERK1/2, p38 and JNK1/2 antibodies at a 1:1000 dilution in Tris-buffered saline (TBS)-0.1% Tween (TBST) and 5% BSA overnight at 4 °C. The membranes were washed, incubated with corresponding secondary anti-rabbit, HRP-conjugated antibody (1:2000) for 1 h at room temperature, and washed for 60 min with TBST. Antibody complexes were visualized using ECL Plus chemiluminescence detection kit. The densities were measured using a scanning densitometer coupled to scanning Software Scion Image (Scion Corporation, Frederick, MD, USA). Standard curves were generated to ensure linearity of signal intensity over the range of protein amounts loaded into gel lanes. Comparisons of densitometric signal intensities were made only within this linearity range.

Immunofluorescent staining and immunohistochemistry

For the animal studies, adult female Wistar rats were used. The animals were maintained under standardized conditions of light (14 h light:10 h darkness cycle,

illumination onset at 0600 h) at 23 °C, with free access to standard pellets and tap water. Rats were sacrificed by decapitation; adrenals were immediately removed, and fixed in Bouin's solution. After fixation tissues were dehydrated in 70, 80, 95% alcohol (45 min each), followed by three times incubation in 100% alcohol (1 h each). This was further cleared in xylene (2×, 1 h each). Then tissues were immersed in paraffin (1 h). Embedding of tissues was performed by a paraffin dispenser DP 500 (Bio-Optica, Milano, Italy). Immunofluorescence staining was performed as previously described (Ramanjaneya *et al.* 2010). The two-stage immunoperoxidase method with EnVision–HRP complex was used. Adrenals were fixed in Bouin's solution for 24 h, embedded in paraffin and sectioned. 5–6 µm-thick sections were deparaffinised and rehydrated. They were boiled in citrate buffer in three steps procedure (pH 6; 3, 3 and 2.5 min). After each boiling step sections were cooled (3×20 min). Further steps were performed in a humidified chamber at room temperature. In order to inhibit endogenous peroxidase activity slides were incubated in 3% solution of hydrogen peroxide for 10 min. Subsequently, non-specific antibody binding sites were blocked by incubation in goat serum for 30 min. The sections were incubated with the primary antibody overnight at 4 °C polyclonal anti-nesfatin-1 (Phoenix Pharmaceuticals, Inc.) antibody, dilution (1:200). Subsequently, the sections were washed in PBS (5×3 min) and incubated with the secondary (peroxidase-conjugated) antibody for 60 min at 37 °C. Peroxidase activity was detected using the DAB technique (Liquid DAB substrate, chromogen system, Dako, Glostrup, Denmark). Nuclei were counterstained with haematoxylin. Control sections were similarly treated with omission of the primary antibody.

Cortisol and aldosterone measurements

Cells were cultured in six-well plates. Cells were starved overnight in serum-free media for 48 h before experiments. Cells were then washed and incubated in fresh serum-free media with either 100 nM nesfatin-1 or forskolin or angiotensin II for the treatment group and with PBS for the control group at timepoints from 6 to 48 h. At the end of each time point, the supernatant was removed and frozen immediately in liquid nitrogen. Cortisol and aldosterone content of media was determined from three different experiments using commercially available ELISA Kits (ALPCO, Salem, NH, USA), according to the manufacturer's instructions, and normalized to the total protein content. The protein concentrations of cell lysates were determined by the

bicinchoninic acid protein quantification assay kit as per manufacturer's protocol (Thermo Scientific, Rockford, MD, USA). The inter- and intra-assay coefficients of variation were <7%.

Cell proliferation assay

H295R and mouse Y1 cells were cultured for 24 h in complete media in 96 wells (1×10^4 cells/well in quadruplet). Prior to treatment, cells were starved overnight in serum free media. Cells were stimulated with indicated concentrations of nesfatin-1 for 24 h at 37 °C/5% CO₂, the following day. The CellTiter-Glo Luminescent Cell Viability assay (Promega UK Ltd) was utilized, according to the manufacturer's instructions. Following incubation, proliferation was quantified via bioluminescence using a luminometer. Non-seeded wells containing media alone were included as a control.

Apoptosis assay

For fluorescent apoptosis/necrosis studies, cells were treated with nesfatin-1 and subsequently stained with 100 nM YO-PRO-1 Iodide apoptotic stain (Molecular Probes, Invitrogen) for 15 min before being visualized and recorded on an Olympus BX61 fluorescent microscope (Olympus). After three 5 min washes with PBS, the slides were mounted with Vectashield mounting medium containing DAPI counter stain (Vector Laboratories Ltd, Peterborough, UK). The slides were examined under an oil immersion objective (40×) and fluorescent signals were analysed using a Zeiss Axioskop 2 microscope (Carl Zeiss Microscopy Ltd, Cambridge, UK) equipped with a cooled CCD camera (CoolSNAP; Photometrics, Tucson, AZ, USA) controlled by a Power Macintosh computer. For each treatment group, between ten and 15 random fields were selected and examined.

Cellular DNA fragmentation assay

Levels of apoptotic cell death were measured by a quantitative sandwich enzyme immunoassay using a commercial kit i.e. Cellular DNA fragmentation ELISA (Roche Diagnostics Ltd). Cells were labeled with bromodeoxyuridine (BrdU) overnight prior to treatments. Following BrdU incorporation, the cells were washed with PBS and incubated with media containing various treatments for 24 h. At the end of the indicated timepoints, cells were permeabilized to release the cytoplasmic DNA fragments into the supernatant. The supernatants

were centrifuged at 300 g for 10 min to bring down the high molecular weight genomic DNA, the low molecular weight BrdU-labeled fragmented DNA released into the supernatants were measured by an ELISA reader (Microplate reader, Molecular Devices, Wokingham, UK) using antibodies against DNA and BrdU.

Calcium measurements

H295R cells were grown to confluence and plated in 96-well black-walled tissue culture plates ~24 h prior to experiments. Relative levels of intracellular Ca^{2+} were measured using the Fluo-4 NW calcium assay kit (Molecular Probes, Invitrogen, Paisley, UK). Cells were loaded with fluo-4 AM in the presence of 2.5 mM probenidol in a commercial phenol-free, magnesium-free Hank's balanced salt solution (HBSS; Invitrogen). The cells were stimulated with various concentrations of nesfatin-1 and fluorescence was measured using a fluorescence plate reader (Tecan GENios, Männedorf, Switzerland; excitation at 485 nm and emission at 520 nm) at room temperature.

Statistical analysis

Data presented in this manuscript are means $\pm$ S.E.M. from three or four different experiments. Data were analyzed by either Student's *t*-test or ANOVA (*post hoc* analysis: Tukey's test), according to the number of groups compared. All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA). $P < 0.05$ was considered significant.

Results

Expression of NUCB2 gene and nesfatin-1 protein in human adrenal gland, rat adrenal gland and in human adrenocortical (H295R) cells

The expression of NUCB2 gene and protein in human adrenal gland and human adrenocortical (H295R) cells was analysed by RT-PCR and western blotting. NUCB2 gene and protein are expressed in both human adrenal gland and in H295R cells; human adipose tissue was used as positive control (Fig. 1A and B). In order to evaluate further the cellular distribution of nesfatin-1 protein in H295R cells, we employed immunohistochemistry using specific antibodies to detect the intracellular distribution of nesfatin-1 in H295R cells. Intense cytoplasmic staining demonstrated the presence of nesfatin-1 protein in the cytoplasm (Fig. 1C). Within rat adrenal gland section

nesfatin-1 immuno-positive substances were present in the cytoplasm of all the zones of adrenal cortex and whilst no reaction was observed in adrenal medulla (Fig. 1D, E, F and G). No apparent expression was evident in the negative controls, confirming staining specificity.

Effects of nesfatin-1 on cortisol and aldosterone secretion from H295R cells

ELISAs were employed to measure cortisol production and aldosterone secretion from H295R cells following stimulation with nesfatin-1 (100 nM) in a time dependent manner. It was evident from our study that nesfatin-1 did not induce any significant changes in either cortisol or aldosterone production compared to basal levels across the time points measured (6, 24, 36 and 48 h). Forskolin (10 μ M) was used as positive control for cortisol secretion, which showed a time dependent increase in cortisol secretion reaching significance at 24 h (Fig. 2A, $^{**}P < 0.01$). Angiotensin II (100 nM) was used as a positive control for aldosterone secretion, which also showed a time dependent increase in aldosterone secretion reaching significance at 24 h (Fig. 2B, $^{**}P < 0.01$).

Effect of nesfatin-1 stimulation on StAR gene expression in H295R cells

Regulation of StAR mRNA expression and translocation into the mitochondria is the first key rate-limiting step in steroid biosynthesis and StAR deficiency is associated with pathophysiology of lipoid congenital adrenal hyperplasia (Manna & Stocco 2005). To assess the relative changes in StAR gene expression following nesfatin-1 treatment, H295R cells were treated with nesfatin-1 (100 nM) for 4 and 24 h. Following agonist stimulation the relative changes in StAR mRNA expression were compared by RT-PCR analysis, which showed no significant changes in StAR expression following nesfatin-1 stimulation (Fig. 2C, $P > 0.05$). Stimulation with angiotensin II (100 nM) used as positive control for 24 h induced significant increase in StAR mRNA expression (Fig. 2B, $^{***}P < 0.001$).

Effect of nesfatin-1 on H295R and Y1 cell viability

Cell proliferation in response to nesfatin-1 (5, 50, 100 nM) stimulation was measured using the CellTiter-Glo Luminescent Cell Viability assay (Promega UK Ltd) at 24 h. Control cells were treated with the same amount of vehicle. Nesfatin-1 significantly inhibited growth of H295R (Fig. 3A, $^{**}P < 0.01$) and Y1 cells (Fig. 3E,

Figure 1

Expression of NUCB2 mRNA, nesfatin-1 protein expression in H295R cells, human adrenal gland and rat adrenal gland. (A) RT-PCR showing the presence of NUCB2 mRNA, (B) western blotting showing nesfatin-1 protein expression in human adipose tissue (h-AT), H295R cells and human adrenal gland (h-AG). Expression data shown in the figure is based on our findings from a sample size of 6. (C) Immunofluorescence of nesfatin-1 in the H295R cell line. (D, E, F and G) Immunohistochemistry showing the presence of nesfatin-1 protein localization in rat adrenal gland. Immunopositive

substances are visible in cytoplasm of adrenocortical cells and in endothelial cells of the cortex. D: cross section through the entire rat adrenal gland. (E) Control section. (F) Higher magnification of the zona glomerulosa (ZG) and zona fasciculata (ZF) (region shown in D), CT – connective tissue capsule. Arrowheads show intense positive reaction in endothelial cells of the capillary bed; G: higher magnification of the zona reticularis (ZR) and medulla (M) (region shown in D). Sections counterstained with haematoxylin. Magnifications defined by scale bars.

* $P < 0.05$) after 24 h compared to vehicle alone. Data points were determined from three independent experiments, each performed in quadruplicate samples and the data points are expressed as percentage decrease over control cells.

Effect of nesfatin-1 on H295R cell apoptosis

Given the previous data, we next assessed if nesfatin-1 promoted apoptosis using a standard DNA fragmentation assay and YO-PRO-1 staining methods. The number of cells stained with YO-PRO-1 (apoptotic green cells) was significantly higher in the nesfatin-1 stimulated group compared to control cells (Fig. 3B). Therefore, we further evaluated the effects of nesfatin-1 (5, 50 and 100 nM) on H295R cells apoptosis using the DNA fragmentation assay. Nesfatin-1 induced a concentration dependent increase in apoptosis of H295R cells compared to control cells at 24 h (Fig. 3D, ** $P < 0.01$). Camptothecin, a known drug to induce apoptosis in various cellular models was used as

a positive control for the assay. Camptothecin (2 μ M) induced a significant increase in apoptosis (Fig. 3D, *** $P < 0.001$). However, when nesfatin-1 was co-incubated with camptothecin, there was no synergistic or additive effects (Fig. 3D, $P > 0.05$). Stimulation of Y1 cells with nesfatin-1 induced apoptosis similar to that observed in H295R cells (Fig. 3F, * $P > 0.05$).

Effects of nesfatin-1 on pro- and anti-apoptotic gene expression in H295R cells

Given the preceding data, we assessed the relative changes in pro- and anti-apoptotic genes expression following nesfatin-1 treatment in H295R cells. H295R cells were stimulated with nesfatin-1 (100 nM) for 4 h, and the relative changes in expression of Bax, BCL-XL, BCL-2 and p53 mRNA expression was assessed by RT-PCR analysis. There was a significant increase in Bax (Fig. 4A, * $P < 0.05$) and significant reductions in BCL-XL (Fig. 4B, ** $P < 0.01$) and of BCL-2 (Fig. 4C, * $P < 0.05$) mRNA expression following

Figure 2

Effects of nesfatin-1 on (A) cortisol and (B) aldosterone secretion from H295R cells. H295R cells (four replicates) were stimulated with nesfatin-1 (100 nM), forskolin (10 μ M) or angiotensin II (Ang II) (100 nM) at 6, 24, 36 and 48 h. At various timepoints media was collected for cortisol and aldosterone assay, and protein lysates from each treatment group were collected for normalization of steroid estimation. (C) Effects of nesfatin-1 on StAR protein (StAR) mRNA levels in H295R cells. Cells were cultured for the indicated periods in the presence or absence of nesfatin-1 (100 nM). StAR mRNA expression levels were normalized against GAPDH mRNA expression. Data are expressed as mean $\pm$ s.e.m., from four independent experiments. * P < 0.05 and ** P < 0.01.

nesfatin-1 stimulation. However, there were no significant changes in p53 mRNA expression (Fig. 4D, P > 0.05).

Effects of nesfatin-1 on intracellular Ca^{2+} levels in H295R cells

Elevation of intracellular calcium through release from intracellular stores such as the endoplasmic reticulum (ER) and a concomitant influx of extracellular Ca^{2+} into the cell (due to the sustained depletion of Ca^{2+} from the ER), have been shown to initiate apoptosis (Furuya *et al.* 1994).

Therefore, we assessed the effects of nesfatin-1 on intracellular Ca^{2+} levels in H295R cells. Nesfatin-1 did not have any significant effects on intracellular Ca^{2+} levels in H295R cells. Angiotensin II (100 nM), used as a positive control, showed an ~ 2.5 -fold increase in intracellular Ca^{2+} levels (Fig. 5).

Role of MAPK signalling pathways in nesfatin-1 mediated H295R cell proliferation and apoptosis

MAPK signalling pathways play a vital role in regulating cell proliferation and apoptosis (Minden *et al.* 1994, Xia *et al.* 1995, Dhillon *et al.* 2007). We employed western blotting to study the effect of nesfatin-1 on key MAPK signalling pathways i.e. ERK_{1/2}, p38 and JNK1/2 pathways. H295R cells were stimulated with nesfatin-1 (100 nM) for 2.5, 5, 15, 30 and 60 min. Nesfatin-1 stimulation decreased ERK_{1/2} phosphorylation, and increased p38 and JNK1/2 phosphorylation in H295R cells (Fig. 6). The immediate, significant effects of nesfatin-1 induced activation of p38 and JNK1/2 and down regulation of ERK1/2 suggest a likely direct physiological role for these MAPK elements.

Discussion

This is the first study demonstrating the expression of NUCB2/nesfatin gene and nesfatin-1 protein in human adrenal gland and human adrenocortical cells (H295R). The distribution of nesfatin-1 in rat adrenal sections appears to be more in adrenal cortex compared to adrenal medulla as observed by immunohistochemistry. Due to abundance of lipid droplets content in zona glomerulosa (ZG) and zona fasciculata (ZF), immunopositive signal seems to be weaker and more diffused in these zones in comparison to zona reticularis (ZR), where the entire cytoplasm is stained. Our results also show strong immunopositive signal in endothelial cells of the capillary bed, especially in ZG and ZF. We also present novel data of nesfatin-1's effects on steroid production, cell viability and apoptosis in human adrenocortical cells (H295R).

Stimulation of H295R cells with nesfatin-1 had no significant effects on glucocorticoid (cortisol) and mineralocorticoid secretions as well as StAR gene expression; the StAR gene encodes for the transport protein that regulates cholesterol transfer within the mitochondria, which is the rate limiting step in the production of steroid hormones. However, nesfatin-1 decreased cell proliferation and induced apoptosis in H295R cells. This is in agreement with a recent study, which showed that nesfatin-1 inhibits ovarian epithelial carcinoma cell

Figure 3

Following overnight serum depletion, H295R cells were stimulated with nesfatin-1 (Nes) (5, 50, 100 nM) and/or camptothecin (CAM) (2 μ M) for 24 h to study the effects of nesfatin-1 on H295R (A) cell viability, (B) and YO-PRO-1 staining (apoptotic cells labeled green), (C) shows signal intensity of the YO-PRO-1 staining in control and nesfatin-1 stimulated cells quantified by ImageJ. Signal intensity of control cells was set to 1.

(D) Concentration dependent effects of nesfatin-1 on DNA fragmentation data in H295R cells. (E) Concentration dependent effects of nesfatin-1 on Y1 cell viability. (F) Concentration dependent effects of nesfatin-1 on DNA fragmentation data in mouse Y1 cells. Data are expressed as mean $\pm$ S.E.M., from three independent experiments, each performed in quadruplicate samples. ** $P < 0.01$ and *** $P < 0.001$.

proliferation (Xu *et al.* 2013). These effects may be tissue and cell type specific as other researchers have found conflicting results in breast cancer cell models (MCF-7 and SK-BR-3), i.e. NUCB2/nesfatin significantly increased cell proliferation as well as migration and invasion properties in MCF-7 and SK-BR-3 cells (Suzuki *et al.* 2012).

Apoptosis is a critical component of adrenal cortical development and remodelling. The adrenal cortex undergoes apoptosis of different zones during fetal and adult life. During postnatal adrenal cortical remodelling, the inner portion of the cortex mainly undergoes apoptosis (Wyllie *et al.* 1973a,b). However, in the adult human adrenal cortex, cellular apoptosis appears to be highest in the external ZG and decreased in the internal ZF and ZR.

Although the reason for this reversal of the apoptotic pattern is unknown, it does suggest that the role of apoptosis in adrenal cortical growth and remodelling may play a key role in tissue remodelling during fetal and adult life. Our findings of nesfatin-1 inducing apoptotic effects on adrenocortical cells may shed some light on the possible role of NUCB2/nesfatin in adrenal remodelling.

Apoptosis is a tightly regulated physiological process in which cell death is executed for the maintenance of a steady state homeostasis under normal physiological conditions, and for responding to various stimuli. Various regulatory proteins control these processes, and genetic aberrations in the control of the transcription of these proteins are present in all cancers (Le Beau *et al.* 1985,

Figure 4

Effects of nesfatin-1 (100 nM) stimulation for 4 h on pro and anti-apoptotic genes expression in H295R cells; mRNA expression levels were normalized against GAPDH mRNA expression. Data are expressed as mean $\pm$ S.E.M., from four independent experiments. * $P < 0.05$ and ** $P < 0.01$.

Figure 5

Effects of nesfatin-1 (Nes) (1, 10, 100 nM) and/or angiotensin II (ANG) (100 nM) on intracellular calcium levels in H295R cells. H295R cells were cultured as described in the methods section. Data are expressed as mean $\pm$ S.E.M., from four independent experiments. Time in (s). A full colour version of this figure is available at <http://dx.doi.org/10.1530/JOE-14-0496>.

Adams & Cory 1998). The members of BCL-2 proteins are potent regulators of the apoptotic process (Adams & Cory 1998, Borner 2003, Donovan & Cotter 2004, Sharpe *et al.* 2004). They consist of both pro- and anti-apoptotic genes that induce opposing effects on mitochondria, including the anti-apoptotic protein Bcl-2 and the pro-apoptotic proteins Bax: BCL-2 family members have the ability to heterodimerize and modify each other's function. Earlier studies have demonstrated an increase in p53 expression and Bax-BCL-2 ratio favouring p53 dependent Bax induced apoptosis (McDonnell *et al.* 1992, Antonsson & Martinou 2000). In addition, p53 has a transcription-independent role in apoptosis induction by promoting

both activation and insertion of Bax into the mitochondrial membrane (Miyashita & Reed 1995). Thus, we investigated whether nesfatin-1 induced apoptosis in H295R cells could be by modulation of the expression of Bax, BCL-XL, BCL-2 and p53 genes. Our results suggest that nesfatin-1 induced apoptosis in H295R cells involves the Bax, BCL-XL and BCL-2 genes. The relevance of these findings on adrenal physiology remains to be explored further. Alterations in intracellular calcium homeostasis due to increased calcium influx or inhibition of calcium efflux is one of the early crucial events involved in apoptosis (Orrenius *et al.* 1992). Therefore, we studied the effects of nesfatin-1 on intracellular calcium levels in H295R cells. We found no significant changes in intracellular calcium levels suggesting that nesfatin-1 induced apoptosis in H295R cells maybe calcium independent. Further experiments are needed to clarify this point. Notably, calcium independent apoptosis has previously been observed in prostate cancer and in cervical cancer cells (Wang *et al.* 2004, Savino *et al.* 2006).

MAPK are crucial for transmission of signal from cell surface receptors to the transcriptional machinery located in the nucleus (Cobb & Goldsmith 1995, Hill & Treisman 1995). MAPK signalling pathways are pivotal in the regulation of cell growth, survival, cell cycle regulation, differentiation and gene expression (Johnson & Vaillancourt 1994). We report for the first time that nesfatin-1 stimulation decreased ERK_{1/2} phosphorylation, and increased p38 and JNK1/2 phosphorylation in H295R cells.

These findings are in agreement with previous reports from various cellular models that have reported the

Figure 6

Effects of nesfatin-1 (100 nM) stimulation on ERK1/2, p38 and JNK1/2 protein phosphorylation and corresponding total protein expressions in H295R cells at 2.5, 5, 15, 30 and 60 min. Western blot analysis of protein extracts from H295R cells demonstrate that the antibody against p-ERK1/2, total ERK1/2, p-p38, total p38, p-JNK1/2 and total JNK1/2 recognized bands

with apparent molecular weights of 42, 44, 43, 43, 46 and 54 kDa, respectively. Data are expressed as mean $\pm$ S.E.M., from three independent experiments. ** P < 0.01 and *** P < 0.001. A full colour version of this figure is available at <http://dx.doi.org/10.1530/JOE-14-0496>.

activation of p38 and JNK1/2 to be associated with programmed cell death and/or necrosis pathways, and the activation of ERK_{1/2} with cell survival pathways (Minden *et al.* 1994, Xia *et al.* 1995, Dhillon *et al.* 2007). Future studies should involve inhibiting p38 and JNK1/2 pathways. It would also be interesting to evaluate the effects of NUCB2/nesfatin in other cancer cell models.

In conclusion, we found that NUCB2/nesfatin is expressed in human adrenal gland and human adrenocortical cells. Stimulation with nesfatin-1 inhibits adrenocortical cell growth and promotes apoptosis, potentially via the involvement of Bax, BCL-XL and BCL-2 genes as well as ERK_{1/2}, p38 and JNK1/2 signalling cascades. This has implications for understanding the role of NUCB2/nesfatin in adrenal zonal development. NUCB2/nesfatin may also be a therapeutic target for adrenal cancer. However, further studies using *in vivo* models are needed to clarify these concepts.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the General Charities of the City of Coventry.

Author contribution statement

M R researched data, contributed to discussion and wrote the manuscript and reviewed/edited the manuscript. B K T contributed to discussion, wrote the manuscript and reviewed/edited the manuscript. M K, J H and V H P researched data and reviewed/edited the manuscript. J K, H L and H S R contributed to discussion and reviewed/edited the manuscript.

Acknowledgements

H S R acknowledges S Waheguru, University of Warwick, for his continual support.

References

- Adams JM & Cory S 1998 The Bcl-2 protein family: arbiters of cell survival. *Science* **281** 1322–1326. (doi:10.1126/science.281.5381.1322)
- Adya R, Tan BK, Chen J & Randeve HS 2012 Protective actions of globular and full-length adiponectin on human endothelial cells: novel insights into adiponectin-induced angiogenesis. *Journal of Vascular Research* **49** 534–543. (doi:10.1159/000338279)
- Antonsson B & Martinou JC 2000 The Bcl-2 protein family. *Experimental Cell Research* **256** 50–57. (doi:10.1006/excr.2000.4839)
- Borner C 2003 The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. *Molecular Immunology* **39** 615–647. (doi:10.1016/S0161-5890(02)00252-3)
- Cetinkaya H, Karagöz B, Bilgi O, Özgün A, Tunçel T, Emirzeoğlu L, Top C & Kandemir EG 2013 Nesfatin-1 in advanced lung cancer patients with weight loss. *Regulatory Peptides* **181** 1–3. (doi:10.1016/j.regpep.2012.11.005)
- Cobb MH & Goldsmith EJ 1995 How MAP kinases are regulated. *Journal of Biological Chemistry* **270** 14843–14846. (doi:10.1074/jbc.270.25.14843)
- Dhillon AS, Hagan S, Rath O & Kolch W 2007 MAP kinase signalling pathways in cancer. *Oncogene* **26** 3279–3290. (doi:10.1038/sj.onc.1210421)
- Donovan M & Cotter TG 2004 Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. *Biochimica et Biophysica Acta* **1644** 133–147. (doi:10.1016/j.bbamcr.2003.08.011)
- Ducsay CA, Hess DL, McClellan MC & Novy MJ 1991 Endocrine and morphological maturation of the fetal and neonatal adrenal cortex in baboons. *Journal of Clinical Endocrinology and Metabolism* **73** 385–395. (doi:10.1210/jcem-73-2-385)
- Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA & Bornstein SR 2004 Fat cells may be the obesity–hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. *Endocrine Research* **30** 865–870. (doi:10.1081/ERC-200044122)
- Elmqvist JK, Coppari R, Balthasar N, Ichinose M & Lowell BB 2005 Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. *Journal of Comparative Neurology* **493** 63–71. (doi:10.1002/cne.20786)
- Furuya Y, Lundmo P, Short AD, Gill DL & Isaacs JT 1994 The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. *Cancer Research* **54** 6167–6175.
- Hill CS & Treisman R 1995 Transcriptional regulation by extracellular signals: mechanisms and specificity. *Cell* **80** 199–211. (doi:10.1016/0092-8674(95)90403-4)
- Johnson GL & Vaillancourt RR 1994 Sequential protein kinase reactions controlling cell growth and differentiation. *Current Opinion in Cell Biology* **6** 230–238. (doi:10.1016/0955-0674(94)90141-4)
- Kargi AY & Iacobellis G 2014 Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications. *International Journal of Endocrinology* **2014** 614074. (doi:10.1155/2014/614074)
- Keegan CE & Hammer GD 2002 Recent insights into organogenesis of the adrenal cortex. *Trends in Endocrinology and Metabolism* **13** 200–208. (doi:10.1016/S1043-2760(02)00602-1)
- Kirschner LS 2002 Signaling pathways in adrenocortical cancer. *Annals of the New York Academy of Sciences* **968** 222–239. (doi:10.1111/j.1749-6632.2002.tb04338.x)
- Könczöl K, Bodnár I, Zelena D, Pintér O, Papp RS, Palkovits M, Nagy GM & Tóth ZE 2010 Nesfatin-1/NUCB2 may participate in the activation of the hypothalamic-pituitary-adrenal axis in rats. *Neurochemistry International* **57** 189–197. (doi:10.1016/j.neuint.2010.04.012)
- Le Beau MM, Westbrook CA, Diaz MO, Rowley JD & Oren M 1985 Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia. *Nature* **316** 826–828. (doi:10.1038/316826a0)
- Lewandowski KC, Stojanovic N, Bienkiewicz M, Tan BK, Prelevic GM, Press M, Tuck S, O'Hare PJ & Randeve HS 2008 Elevated concentrations of retinol-binding protein-4 (RBP-4) in gestational diabetes mellitus: negative correlation with soluble vascular cell adhesion molecule-1 (sVCAM-1). *Gynecological Endocrinology* **24** 300–305. (doi:10.1080/09513590802141052)
- Maisey MN & Lessof MH 1969 Thyroid function in Addison's disease. *BMJ* **3** 392–393. (doi:10.1136/bmj.3.5667.392)
- Manna PR & Stocco DM 2005 Regulation of the steroidogenic acute regulatory protein expression: functional and physiological consequences. *Current Drug Targets. Immune, Endocrine and Metabolic Disorders* **5** 93–108. (doi:10.2174/1568008053174714)
- McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM & Campbell ML 1992 Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. *Cancer Research* **52** 6940–6944.
- Minden A, Lin A, Smeal T, Dérijard B, Cobb M, Davis R & Karin M 1994 c-Jun N-terminal phosphorylation correlates with activation of the

- JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. *Molecular and Cellular Biology* **14** 6683–6688.
- Miyashita T & Reed JC 1995 Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. *Cell* **80** 293–299. (doi:10.1016/0092-8674(95)90513-8)
- Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K *et al.* 2006 Identification of nesfatin-1 as a satiety molecule in the hypothalamus. *Nature* **443** 709–712. (doi:10.1038/nature05162)
- Orrenius S, McCabe MJ Jr & Nicotera P 1992 Ca(2+)-dependent mechanisms of cytotoxicity and programmed cell death. *Toxicology Letters* **64–65**. Spec No. 357–364. (doi:10.1016/0378-4274(92)90208-2)
- Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Research* **29** e45. (doi:10.1093/nar/29.9.e45)
- Rainey WE, Bird IM & Mason JI 1994 The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. *Molecular and Cellular Endocrinology* **100** 45–50. (doi:10.1016/0303-7207(94)90277-1)
- Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK *et al.* 2010 Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. *Endocrinology* **151** 3169–3180. (doi:10.1210/en.2009-1358)
- Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N & Lehnert H 2012 Cardiometabolic aspects of the polycystic ovary syndrome. *Endocrine Reviews* **33** 812–841. (doi:10.1210/en.2009-1358)
- Savino JA III, Evans JF, Rabinowitz D, Auborn KJ, Carter TH, Evans JF, Rabinowitz D, Auborn KJ & Carter TH 2006 Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. *Molecular Cancer Therapeutics* **5** 556–563. (doi:10.1158/1535-7163.MCT-05-0355)
- Sharpe JC, Arnoult D & Youle RJ 2004 Control of mitochondrial permeability by Bcl-2 family members. *Biochimica et Biophysica Acta* **1644** 107–113. (doi:10.1016/j.bbamcr.2003.10.016)
- Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T *et al.* 2009 Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. *Endocrinology* **150** 662–671. (doi:10.1210/en.2008-0598)
- Stengel A & Taché Y 2011 Minireview: nesfatin-1—an emerging new player in the brain-gut, endocrine, and metabolic axis. *Endocrinology* **152** 4033–4038. (doi:10.1210/en.2011-1500)
- Sucheston ME & Cannon MS 1968 Development of zonular patterns in the human adrenal gland. *Journal of Morphology* **126** 477–491. (doi:10.1002/jmor.1051260408)
- Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H & Suzuki T 2012 Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. *Cancer Science* **103** 136–143. (doi:10.1111/j.1349-7006.2011.02119.x)
- Tan BK, Adya R, Shan X, Syed F, Lewandowski KC, O'Hare JP & Randeva HS 2009 *Ex vivo* and *in vivo* regulation of lipocalin-2, a novel adipokine, by insulin. *Diabetes Care* **32** 129–131. (doi:10.2337/dc08-1236)
- Tan BK, Hallschmid M, Kern W, Lehnert H & Randeva HS 2011 Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. *Journal of Clinical Endocrinology and Metabolism* **96** E669–E673. (doi:10.1210/jc.2010-1782)
- Wang H, Chen X & Bai X 2004 Hepatic cell apoptosis was triggered by HBx accumulation and independent on verapamil. *Journal of Huazhong University of Science and Technology. Medical Sciences* **24** 281–283. (doi:10.1007/BF02832013)
- Wyllie AH, Kerr JF & Currie AR 1973a Cell death in the normal neonatal rat adrenal cortex. *Journal of Pathology* **111** 255–261. (doi:10.1002/path.1711110406)
- Wyllie AH, Kerr JF, Macaskill IA & Currie AR 1973b Adrenocortical cell deletion: the role of ACTH. *Journal of Pathology* **111** 85–94. (doi:10.1002/path.1711110203)
- Xia Z, Dickens M, Raingeaud J, Davis RJ & Greenberg ME 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science* **270** 1326–1331. (doi:10.1126/science.270.5240.1326)
- Xu Y, Pang X, Dong M, Wen F & Zhang Y 2013 Nesfatin-1 inhibits ovarian epithelial carcinoma cell proliferation *in vitro*. *Biochemical and Biophysical Research Communications* **440** 467–472. (doi:10.1016/j.bbrc.2013.06.001)
- Zhang H, Qi C, Li L, Luo F & Xu Y 2013a Clinical significance of NUCB2 mRNA expression in prostate cancer. *Journal of Experimental & Clinical Cancer Research* **32** 56. (doi:10.1186/1756-9966-32-56)
- Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y & Xu Y 2013b Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. *Journal of Experimental & Clinical Cancer Research* **32** 77. (doi:10.1186/1756-9966-32-77)
- Zhang H, Qi C, Wang A, Li L & Xu Y 2014 High expression of nucleobindin 2 mRNA: an independent prognostic factor for overall survival of patients with prostate cancer. *Tumour Biology* **35** 2025–2028. (doi:10.1007/s13277-013-1268-z)

Received in final form 24 March 2015

Accepted 30 March 2015

Accepted Preprint published online 13 March 2015